Get started
Author

Chia‐Lun Chang

Observed names: C.-L. Chang, C.L. Chang
ORCID: 0000-0002-5280-7733
Observed ORCID: 0000-0002-5280-7733
OpenAlex ID: A5111060807
1325P Sunvozertinib as first-line treatment in NSCLC patients with EGFR Exon20 insertion mutations
2023 · J.C-H. Yang, M. Wang, et al. · Annals of Oncology · 15
PDF
Cumulative Dose of Regorafenib in Patients With Metastatic Colorectal Cancer: A Multicenter Cohort Study
2025 · Yu‐Hsuan Kuo, Chun‐Nan Kuo, et al. · Journal of Gastroenterology and Hepatology · 1
Effectiveness and Safety of Reduced and Standard Initial Doses of Regorafenib in Patients With Metastatic Colorectal Cancer: A Multicenter Retrospective Study in Taiwan
2025 · Yu‐Hsuan Kuo, Chun‐Nan Kuo, et al. · Pharmacoepidemiology and Drug Safety
Long-term outcomes of three-dimensional conformal radiotherapy-based and intensity-modulated radiotherapy-based concurrent chemoradiotherapy in patients with thoracic esophageal squamous cell carcinoma
2019 · C.-L. Chang, S.-Y. Wu · Annals of Oncology
PDF
Curative Therapy Improves Survival of Elderly Patients With Locally Advanced Head and Neck Cancer and a High Comorbidity Index
2016 · S.Y. Wu, C.L. Chang, et al. · International Journal of Radiation Oncology*Biology*Physics
PDF
Works count: 5
Citation count: 16
H-index: 1
I10-index: 1
Year
Topic
Type